Daniel J Ceradini, MD

Daniel-J-Ceradini,MDAssistant Professor of Plastic Surgery
Director of Composite Tissue Allotransplantation
Director of IRPS Laboratories
Associate Director of Microsurgery
M.D., 2000 New York University School of Medicine

New York University School of Medicine
560 First Avenue
TH-169
New York, NY 10016
Office Tel: (212) 263-5834
Lab Tel: (212) 263-8745
E-mail: Ceradd01@nyumc.org

Website: http://www.med.nyu.edu/biosketch/ceradd01#

Research Theme(s): Stem Cell Biology, Vascular Biology, Transplant Biology
Keywords: Tissue Regeneration, Stem Cell Trafficking, Composite Tissue Allotransplantation, Tissue Engineering, Hypoxia, Diabetes, Aging, Wound Healing

Research Summary:

Organismal development, growth, and tissue regeneration following injury is critically dependent on plasticity of vascular networks and local tissue oxygen tension.  In specific disease states such as diabetes or in advanced aging, this plasticity is significantly altered, resulting in a diminished ability to repair damaged tissues.  In tissue and organ engineering, the presence of a functional vasculature is the most significant rate-limiting step in generating substantial constructs ex vivo as well as their integration into the host vasculature in vivo.  In composite tissue allotransplantation, the interplay between the allograft vasculature and host immune system plays a critical role in the rejection response.   Thus, we believe that understanding the mechanisms of stem/progenitor mediated vascular regeneration and the interplay between the vasculature and circulating/resident stem cells has a broad impact on human disease and tissue engineering.

Our lab investigates novel methods to modulate stem cells and/or their functional environment using several preclinical models in mice and rats.   Specifically, we are interested in the impact of oxygen tension on stem/progenitor function and how this can be exploited to restore vascular regeneration in disease states and facilitate “re-engineering” of tissue constructs to generate tolerant replacement parts.  As clinical surgeons, we also have abundant access to multiple human tissue types which are frequently used to support our animal findings.  The surgeon-scientist paradigm is unique in that we are in a position to rapidly translate ideas and innovation from the laboratory to clinical trials to really make an impact in the care of patients.

Selected Publications: